Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria
- PMID: 17462641
- DOI: 10.1016/j.fertnstert.2007.01.032
Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria
Abstract
Objective: To determine the risk of metabolic complications, primarily metabolic syndrome, in all polycystic ovary syndrome (PCOS) phenotypes compared with control subjects.
Design: Retrospective chart review.
Setting: University practice.
Patient(s): Women with PCOS (Rotterdam definition; n = 258) and women without PCOS seen during the same time period for an annual exam used as controls (n = 110).
Intervention(s): None.
Main outcome measure(s): Metabolic syndrome.
Result(s): Three PCOS phenotypes had a significantly higher prevalence of metabolic syndrome compared with the control subjects: oligomenorrhea/oligo-ovulation (O) + hyperandrogenism (H) + polycystic ovaries (P), age-adjusted odds ratio [OR] 6.3 (95% confidence interval 2.1-18.9); O+H, OR 7.8 (2.2-27.5); and H+P, OR 8.2 (2.3-29.3). There was no significant difference in the prevalence of metabolic syndrome between women with O+P and control subjects, even in obese women. The prevalence of insulin resistance and glucose intolerance was not significantly different between POCS phenotypes
Conclusion(s): The risk of metabolic syndrome may vary among the four phenotypes of PCOS based on the Rotterdam criteria. This new information may be of relevance in counseling women with PCOS although larger studies may be needed to validate our findings.
Similar articles
-
The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.Clin Endocrinol (Oxf). 2008 Jul;69(1):52-60. doi: 10.1111/j.1365-2265.2007.03145.x. Epub 2008 Jul 1. Clin Endocrinol (Oxf). 2008. PMID: 18034780
-
Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.Clin Endocrinol (Oxf). 2007 Apr;66(4):513-7. doi: 10.1111/j.1365-2265.2007.02764.x. Clin Endocrinol (Oxf). 2007. PMID: 17371468
-
Increased risk of depressive disorders in women with polycystic ovary syndrome.Fertil Steril. 2007 Jun;87(6):1369-76. doi: 10.1016/j.fertnstert.2006.11.039. Epub 2007 Mar 29. Fertil Steril. 2007. PMID: 17397839
-
Metabolic syndrome in polycystic ovary syndrome.Minerva Ginecol. 2006 Apr;58(2):109-14. Minerva Ginecol. 2006. PMID: 16582867 Review.
-
Obesity and the polycystic ovary syndrome.Minerva Endocrinol. 2007 Sep;32(3):129-40. Minerva Endocrinol. 2007. PMID: 17912153 Review.
Cited by
-
Lack of adequate counseling about pregnancy complications in patients with polycystic ovary syndrome: a cross-sectional survey study.F S Rep. 2024 May 18;5(3):312-319. doi: 10.1016/j.xfre.2024.05.004. eCollection 2024 Sep. F S Rep. 2024. PMID: 39381657 Free PMC article.
-
Carotid intima-media thickness in mainly non-obese women with polycystic ovary syndrome and age-matched controls.Obstet Gynecol Sci. 2013 Jul;56(4):249-55. doi: 10.5468/ogs.2013.56.4.249. Epub 2013 Jul 15. Obstet Gynecol Sci. 2013. PMID: 24328010 Free PMC article.
-
Diagnostic Performance of Ovarian Morphology on Ultrasonography across Anovulatory Conditions-Impact of Body Mass Index.Diagnostics (Basel). 2023 Jan 19;13(3):374. doi: 10.3390/diagnostics13030374. Diagnostics (Basel). 2023. PMID: 36766481 Free PMC article.
-
Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.Hum Reprod Update. 2014 Sep-Oct;20(5):748-58. doi: 10.1093/humupd/dmu012. Epub 2014 Mar 30. Hum Reprod Update. 2014. PMID: 24688118 Free PMC article.
-
Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women.PLoS One. 2021 Feb 26;16(2):e0246862. doi: 10.1371/journal.pone.0246862. eCollection 2021. PLoS One. 2021. PMID: 33635862 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical